Healthcare / Medical Instruments & SuppliesNasdaqCM
$3.69
+0.03 (+0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $752000.00 · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$40M
P/E
52.7x
↑EV/EBITDA
25.9x
↑ROE
11.7%
↑Gross Margin
61.9%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
8.8%
FCF / Net income
1.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.8M · net income $1.2M · FCF $1.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $18.8M | $18.8M | $14.2M | $14.2M | $10.0M | $10.2M | $8.6M | $10.3M | $5.7M | $3.8M | $2.3M | $1.9M | $1.7M | $1.7M | $1.8M | $2.2M | $2.9M | — |
| Net Income | $1.2M | $1.2M | $74000.00 | $-1.6M | $-7.4M | $-3.9M | $-4.5M | $-3.2M | $-3.4M | $-809000.00 | $-3.0M | $-3.1M | $-7.4M | $1.3M | $-6.6M | $-7.0M | $3.9M | $-12.1M |
| EBITDA | $1.3M | $1.3M | $227000.00 | $-1.4M | $-3.9M | $-3.1M | $-4.1M | $-3.0M | $-2.9M | $-2.0M | $-2.9M | $-3.4M | $-2.7M | $-3.3M | $-3.3M | $-2.2M | — | — |
| EPS | — | — | 0.01 | -0.15 | -0.70 | -0.41 | — | — | — | — | — | — | -2.79 | -1.62 | — | — | 16.74 | — |
| Gross Margin | 61.9% | 61.9% | 61.6% | 59.0% | 47.4% | 55.1% | 57.4% | 58.9% | 56.3% | 60.2% | 55.8% | 54.5% | 68.6% | 48.4% | 59.2% | 39.2% | 38.2% | — |
| Operating Margin | 6.1% | 6.1% | 0.0% | -11.2% | -43.5% | -31.8% | -49.9% | -30.5% | -53.0% | -58.4% | -123.7% | -176.0% | -152.7% | -190.6% | -184.4% | -104.3% | -64.3% | — |
| Net Margin | 6.4% | 6.4% | 0.5% | -11.1% | -74.0% | -37.8% | -52.9% | -30.8% | -59.8% | -21.2% | -130.7% | -158.8% | -421.7% | 76.0% | -366.5% | -316.1% | 132.1% | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.10 | 0.10 | 0.16 | 0.22 | 0.20 | 0.03 | 0.05 | 0.18 | 0.27 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.55 | 4.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $1.6M | $1.6M | $-547000.00 | $752000.00 | $-3.4M | $-1.5M | $-7.1M | $-2.3M | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 11.7% | 11.7% | 0.9% | -18.8% | -132.0% | -33.1% | -36.1% | -68.0% | -89.6% | -41.5% | -454.6% | 115.9% | 129.7% | -35.5% | 1113.1% | -492.5% | 2874.1% | -617.1% |
| Valuation | ||||||||||||||||||
| P/E | 52.71 | 52.71 | 154.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 25.94 | 25.94 | 61.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.85 | 3.85 | 1.90 | 4.24 | 2.04 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 32.7% | 32.7% | -0.5% | 42.7% | — | 19.3% | -17.2% | 81.7% | 49.3% | 64.2% | 19.3% | 11.2% | 0.5% | -3.7% | -18.4% | -24.6% | — | — |
| EPS Growth | — | — | 106.7% | 78.6% | — | — | — | — | — | — | — | — | -72.2% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+35.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
+35.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.